Results of Operations and Financial Condition. On August 14, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2027 first quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for pur…

Other Events On August 6, 2026, the Company announced the topline results of its three-arm, multicenter, randomized, double-blind, placebo controlled exploratory Phase 2 clinical trial (N=61) designed to assess the efficacy, safety, and tolerability of two 3.2 µg doses of fasedienol administered ten minutes apart compared with a single 3.2 µg dose and placebo, for the acute treatment of anxiety induced by a public speaking challenge. The study was not designed to demonstrate statistically sig…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On August 4, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) received an extension notification (the “ Extension Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) granting the Company a 180-day extension, until February 1, 2027 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per…

Director — Douglas J. Williamson, M.D.: Dr. Douglas J. Williamson was appointed as a director of Vistagen Therapeutics, Inc.

Director — Ms. Margaret FitzPatrick, Dr. Joanne Curley: Two directors decided not to stand for re-election at the annual meeting.

of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Chief Medical Officer — Angel S. Angelov, M.D., MBA: Vistagen Therapeutics appointed Dr. Angelov as the new Chief Medical Officer.

The filing describes the approval of retention awards in the form of stock option grants to certain executives and employees.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Re…

Director — Mary Rotunno: Mary Rotunno resigned from the Board of Directors.

Other Events On March 5, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) implemented a Board approved reduction in its workforce by approximately 20%. The reduction is intended to provide disciplined cash management while prioritizing efficient execution of ongoing clinical studies in the Company’s PALISADE Program for fasedienol for the acute treatment of social anxiety disorder. The Company expects topline results from its PALISADE-4 Phase 3 trial in the first half of 2026 and expects c…

Director — Paul Edick: Paul Edick resigned from the Board of Directors.

Results of Operations and Financial Condition. On February 12, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2026 third quarter ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” f…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 3, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“ Common Stock ”), for the last 30 consecutive business days, the Company is not currently in complianc…

Chief Financial Officer and Treasurer — Nick B. Tressler: The company hired a new Chief Financial Officer and Treasurer.

Results of Operations and Financial Condition. On November 13, 2025, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2026 second quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed”…

Director — Paul R. Edick: Mr. Paul R. Edick was appointed as a director and to serve on the Audit and Compensation Committees.

Chief Financial Officer and principal financial and accounting officer — Cynthia L. Anderson: Ms. Anderson resigned from her position as CFO and principal financial and accounting officer.

Results of Operations and Financial Condition. On August 7, 2025, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2026 first quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Chief Corporate Development Officer — Elissa Cote: Ms. Elissa Cote was appointed as the Chief Corporate Development Officer.

Results of Operations and Financial Condition. On February 13, 2025, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2025 third quarter ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Results of Operations and Financial Condition. On November 7, 2024, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2025 second quarter ended September 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed”…

Results of Operations and Financial Condition. On August 13, 2024, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year 2025 first quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for pur…

Change in Registrant ’ s Certifying Accountant (a) Dismissal of Independent Registered Public Accounting Firm On July 8, 2024, following the completion of a competitive selection process conducted by the Audit Committee of the Board of Directors (the “ Audit Committee ”) of Vistagen Therapeutics, Inc. (the “ Company ”) to determine the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2025, the Company selected KPMG LLP (“ KPMG ”) to serve as the Com…

Results of Operations and Financial Condition. On June 11, 2024, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal year ended March 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18…